Tyrosin Kinase inhibitors (TKI), have dramatically changed the natural history of chronic myeloid leukemia
(CML) leading to an impressive increase in overall survival rates and allowing many CML patients to achieve a close-tonormal
life expectancy. Unfortunately, there is growing evidence that these drugs are not curative, about 30-35% of the
patients who receive imatinib become resistant or discontinue the drug because of side effects; moreover, 15% of all
patients become resistant to all TKIs, a condition which represents the biggest challenge in CML treatment. Recent
progresses in CML stem cell biology have identified new agents and therapeutic strategies that can be used to target the
CML stem cell compartment. These studies have opened new perspectives and have highlighted key strategies for
treating, and possibly curing, CML in the upcoming years.